Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $34.78.

Several research analysts recently weighed in on the stock. BMO Capital Markets restated an “outperform” rating and set a $32.00 price target on shares of Xencor in a report on Tuesday, August 6th. Royal Bank of Canada boosted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Wedbush restated an “outperform” rating and set a $34.00 price target on shares of Xencor in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st.

Institutional Trading of Xencor

Several hedge funds have recently added to or reduced their stakes in XNCR. Darwin Global Management Ltd. bought a new stake in shares of Xencor in the first quarter valued at approximately $24,557,000. Logos Global Management LP raised its position in shares of Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after purchasing an additional 850,000 shares during the period. Point72 Asset Management L.P. raised its position in shares of Xencor by 52.9% in the second quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after purchasing an additional 436,389 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Xencor by 9.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares during the period. Finally, Baker BROS. Advisors LP raised its position in shares of Xencor by 122.2% in the first quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock valued at $12,070,000 after purchasing an additional 300,000 shares during the period.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $21.16 on Friday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -9.66 and a beta of 0.67. The company has a 50-day moving average price of $19.51 and a 200-day moving average price of $20.11. Xencor has a 1 year low of $15.31 and a 1 year high of $26.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The business had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm’s quarterly revenue was down 62.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.37) earnings per share. On average, equities research analysts forecast that Xencor will post -4.11 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.